BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26077730)

  • 1. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
    Drapeau A; Fortin D
    Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
    Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
    Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
    Karim R; Palazzo C; Evrard B; Piel G
    J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.
    Ferguson S; Lesniak MS
    Curr Drug Deliv; 2007 Apr; 4(2):169-80. PubMed ID: 17456036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.
    Zhan C; Lu W
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2380-7. PubMed ID: 23016643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
    Juratli TA; Schackert G; Krex D
    Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
    Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
    ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming the blood-brain barrier for chemotherapy: limitations, challenges and rising problems.
    Wang Z; Sun H; Yakisich JS
    Anticancer Agents Med Chem; 2014; 14(8):1085-93. PubMed ID: 23092271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.
    Serwer LP; James CD
    Adv Drug Deliv Rev; 2012 May; 64(7):590-7. PubMed ID: 22306489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetrating the Blood-Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy.
    Tam DY; Ho JW; Chan MS; Lau CH; Chang TJH; Leung HM; Liu LS; Wang F; Chan LLH; Tin C; Lo PK
    ACS Appl Mater Interfaces; 2020 Jul; 12(26):28928-28940. PubMed ID: 32432847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.
    Ciordia R; Supko J; Gatineau M; Batchelor T
    Curr Oncol Rep; 2000 Sep; 2(5):445-53. PubMed ID: 11122877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.
    Cooper I; Last D; Guez D; Sharabi S; Elhaik Goldman S; Lubitz I; Daniels D; Salomon S; Tamar G; Tamir T; Mardor R; Fridkin M; Shechter Y; Mardor Y
    J Cereb Blood Flow Metab; 2015 Jun; 35(6):967-76. PubMed ID: 25669901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy.
    Lamsam L; Johnson E; Connolly ID; Wintermark M; Hayden Gephart M
    Neurosurg Focus; 2018 Feb; 44(2):E10. PubMed ID: 29385922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
    Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
    Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.